OBJECTIVES: To quantify the association between systemic levels of the chemokine regulated on activation normal T-cell expressed and secreted (RANTES/CCL5), interferon-γ-inducible protein-10 (IP-10/CXCL10), monocyte chemoattractant protein-1 (MCP-1/CCL2), and eotaxin-1 (CCL11) with future coronary heart disease (CHD) and ischemic stroke events and to assess their usefulness for CHD and ischemic stroke risk prediction in the PRIME Study. METHODS:After 10 years of follow-up of 9,771 men, 2 nested case-control studies were built including 621 first CHD events and 1,242 matched controls and 95 first ischemic stroke events and 190 matched controls. Standardized hazard ratios (HRs) for each log-transformed chemokine were estimated by conditional logistic regression. RESULTS: None of the 4 chemokines were independent predictors of CHD, either with respect to stable angina or to acute coronary syndrome. Conversely, RANTES (HR = 1.70; 95% confidence interval [CI] 1.05-2.74), IP-10 (HR = 1.53; 95% CI 1.06-2.20), and eotaxin-1 (HR = 1.59; 95% CI 1.02-2.46), but not MCP-1 (HR = 0.99; 95% CI 0.68-1.46), were associated with ischemic stroke independently of traditional cardiovascular risk factors, hs-CRP, and fibrinogen. When the first 3 chemokines were included in the same multivariate model, RANTES and IP-10 remained predictive of ischemic stroke. Their addition to a traditional risk factor model predicting ischemic stroke substantially improved the C-statistic from 0.6756 to 0.7425 (p = 0.004). CONCLUSIONS: In asymptomatic men, higher systemic levels of RANTES and IP-10 are independent predictors of ischemic stroke but not of CHD events. RANTES and IP-10 may improve the accuracy of ischemic stroke risk prediction over traditional risk factors.
RCT Entities:
OBJECTIVES: To quantify the association between systemic levels of the chemokine regulated on activation normal T-cell expressed and secreted (RANTES/CCL5), interferon-γ-inducible protein-10 (IP-10/CXCL10), monocyte chemoattractant protein-1 (MCP-1/CCL2), and eotaxin-1 (CCL11) with future coronary heart disease (CHD) and ischemic stroke events and to assess their usefulness for CHD and ischemic stroke risk prediction in the PRIME Study. METHODS: After 10 years of follow-up of 9,771 men, 2 nested case-control studies were built including 621 first CHD events and 1,242 matched controls and 95 first ischemic stroke events and 190 matched controls. Standardized hazard ratios (HRs) for each log-transformed chemokine were estimated by conditional logistic regression. RESULTS: None of the 4 chemokines were independent predictors of CHD, either with respect to stable angina or to acute coronary syndrome. Conversely, RANTES (HR = 1.70; 95% confidence interval [CI] 1.05-2.74), IP-10 (HR = 1.53; 95% CI 1.06-2.20), and eotaxin-1 (HR = 1.59; 95% CI 1.02-2.46), but not MCP-1 (HR = 0.99; 95% CI 0.68-1.46), were associated with ischemic stroke independently of traditional cardiovascular risk factors, hs-CRP, and fibrinogen. When the first 3 chemokines were included in the same multivariate model, RANTES and IP-10 remained predictive of ischemic stroke. Their addition to a traditional risk factor model predicting ischemic stroke substantially improved the C-statistic from 0.6756 to 0.7425 (p = 0.004). CONCLUSIONS: In asymptomatic men, higher systemic levels of RANTES and IP-10 are independent predictors of ischemic stroke but not of CHD events. RANTES and IP-10 may improve the accuracy of ischemic stroke risk prediction over traditional risk factors.
Authors: Rajat Deo; Amit Khera; Darren K McGuire; Sabina A Murphy; Januario de P Meo Neto; David A Morrow; James A de Lemos Journal: J Am Coll Cardiol Date: 2004-11-02 Impact factor: 24.094
Authors: Florence Canouï-Poitrine; Gerald Luc; Jean-Marie Bard; Jean Ferrieres; John Yarnell; Dominique Arveiler; Pierre Morange; Frank Kee; Alun Evans; Philippe Amouyel; Pierre Ducimetiere; Jean-Philippe Empana Journal: Cerebrovasc Dis Date: 2010-07-23 Impact factor: 2.762
Authors: Helena Kervinen; Matti Mänttäri; Maija Kaartinen; Heikki Mäkynen; Timo Palosuo; Kari Pulkki; Petri T Kovanen Journal: Am J Cardiol Date: 2004-10-15 Impact factor: 2.778
Authors: S Matthijs Boekholdt; Ron J G Peters; C Erik Hack; Nicholas E Day; Robert Luben; Sheila A Bingham; Nicholas J Wareham; Pieter H Reitsma; Kay-Tee Khaw Journal: Arterioscler Thromb Vasc Biol Date: 2004-06-03 Impact factor: 8.311
Authors: Yanli Li; Matthew R Bonner; Richard W Browne; Furong Deng; Lili Tian; Junfeng Jim Zhang; Mya Swanson; Kate Rittenhouse-Olson; Zeinab Farhat; Lina Mu Journal: Biomarkers Date: 2019-09-15 Impact factor: 2.658
Authors: Andrea Rocco; Peter A Ringleb; Ulrike Grittner; Christian H Nolte; Alice Schneider; Simon Nagel Journal: Neurol Sci Date: 2015-07-25 Impact factor: 3.307
Authors: Marios K Georgakis; Dipender Gill; Kristiina Rannikmäe; Matthew Traylor; Christopher D Anderson; Jin-Moo Lee; Yoichiro Kamatani; Jemma C Hopewell; Bradford B Worrall; Jürgen Bernhagen; Cathie L M Sudlow; Rainer Malik; Martin Dichgans Journal: Circulation Date: 2019-01-08 Impact factor: 29.690